Overview

A Phase II Clinical Trial of Hydronidone Capsules(F351) in Patients With Liver Fibrosis Induced by HBV Chronic Hepatitis

Status:
Unknown status
Trial end date:
2017-07-01
Target enrollment:
Participant gender:
Summary
To explore the effective dose and safety of the effect of hydronidone and entecavir on hepatic fibrosis in chronic viral hepatitis B.
Phase:
Phase 2
Details
Lead Sponsor:
Shanghai Genomics, Inc.
Treatments:
Entecavir